These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 33934963)
1. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis. Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963 [TBL] [Abstract][Full Text] [Related]
2. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. Thomas AZ; Adibi M; Slack RS; Borregales LD; Merrill MM; Tamboli P; Sircar K; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA J Urol; 2016 Sep; 196(3):678-84. PubMed ID: 27036304 [TBL] [Abstract][Full Text] [Related]
3. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360 [TBL] [Abstract][Full Text] [Related]
4. The impact of metastasectomy on survival of patients with synchronous metastatic renal cell cancer in Finland: A nationwide study. Laru L; Ronkainen H; Ohtonen P; Vaarala MH Scand J Surg; 2024 Sep; 113(3):219-228. PubMed ID: 38433655 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: A systematic review and meta-analysis. Zhao Y; Li J; Li C; Fan J; Liu L Int J Surg; 2017 May; 41():70-77. PubMed ID: 28351779 [TBL] [Abstract][Full Text] [Related]
6. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Zaid HB; Parker WP; Safdar NS; Gershman B; Erwin PJ; Murad MH; Boorjian SA; Costello BA; Thompson RH; Leibovich BC J Urol; 2017 Jan; 197(1):44-49. PubMed ID: 27473875 [TBL] [Abstract][Full Text] [Related]
7. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study. Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226 [TBL] [Abstract][Full Text] [Related]
8. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. Takagi T; Fukuda H; Ishihara H; Yoshida K; Kondo T; Kobayashi H; Iizuka J; Okumi M; Ishida H; Omae K; Tanabe K Urol Oncol; 2020 May; 38(5):515-520. PubMed ID: 32146128 [TBL] [Abstract][Full Text] [Related]
9. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840 [TBL] [Abstract][Full Text] [Related]
15. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124 [TBL] [Abstract][Full Text] [Related]
17. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955 [TBL] [Abstract][Full Text] [Related]
18. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis. Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610 [TBL] [Abstract][Full Text] [Related]
19. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909 [TBL] [Abstract][Full Text] [Related]
20. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis. Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]